Annexon, Inc. Share Price
ANNXAnnexon, Inc. Stock Performance
Open $5.13 | Prev. Close $5.07 | Circuit Range N/A |
Day Range $4.96 - $5.13 | Year Range $1.29 - $5.47 | Volume 2,17,979 |
Average Traded $5.04 |
Annexon, Inc. Share Price Chart
About Annexon, Inc.
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company's lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.
Annexon, Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
06-Jan-26 | $5.13 | $5.11 | +0.00% |
06-Jan-26 | $5.13 | $5.11 | -2.29% |
05-Jan-26 | $4.75 | $5.23 | +11.75% |
02-Jan-26 | $5.09 | $4.68 | -6.59% |
31-Dec-25 | $5.02 | $5.01 | -0.79% |
30-Dec-25 | $4.99 | $5.05 | +1.20% |
29-Dec-25 | $5.08 | $4.99 | -2.44% |